Skip to main content
. 2017 May 11;12(5):e0173222. doi: 10.1371/journal.pone.0173222

Fig 5. Intramyocardial transplantation of iPSC derived CMs alleviates adverse myocardial remodeling and increases the amount of viable myocardium.

Fig 5

A: Infarct size (%): after 2 days (MRI): PBS28 = 34±3; iPSC-CM28 = 36±4; after 28 days (Masson’s): PBS28 = 46±3; iPSC-CM28 = 25±4 B: LV wall thickness after 28 days (Masson’s; μm): iPSC-CM7 = 990±57; iPSC-CM28 = 669±64; PBS28 = 328±12 C: Expansion index after 28 days (Masson’s): iPSC-CM7 = 1.1±0.1; iPSC-CM28 = 2.9±0.5; PBS28 = 4.5±0.4 D: Viable myocardium (Masson’s; % of infarct area): iPSC-CM7 = 32±2; iPSC-CM28 = 46±1; PBS28 = 15±1. iPSC-CM28 vs. PBS28: * P<0.05, ** P<0.01, **** P<0.0001. iPSC-CM7 vs. iPSC-CM28: # P<0.05, ##P<0.01; ###P<0.001; ####P<0.0001.